Global Alirocumab Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Alirocumab Market Size

• The global alirocumab market size was valued at USD 1.16 billion in 2024 and is expected to reach USD 2.44 billion by 2032, at a CAGR of 9.8% during the forecast period
• This growth is driven by factors such as the rising prevalence of cardiovascular diseases and growing adoption of PCSK9 inhibitors

Alirocumab Market Analysis

• Alirocumab is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme involved in cholesterol regulation. It is used as an adjunct to diet and statin therapy to lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, heterozygous familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD)
• The global alirocumab market is experiencing steady growth due to the increasing prevalence of cardiovascular diseases, rising cholesterol-related health concerns, and growing awareness of PCSK9 inhibitors
• North America is expected to dominate the alirocumab market with a market share of approximately 40.4%, driven by the high prevalence of cardiovascular diseases, increased awareness of lipid-lowering therapies, and the strong presence of key pharmaceutical companies such as Sanofi and Regeneron
• Asia-Pacific is expected to be the fastest growing region in the alirocumab market, with a projected market share of approximately 24.6% in 2025, driven by the rapid expansion of healthcare infrastructure, increasing prevalence of cardiovascular diseases, and growing awareness of cholesterol-lowering therapies
• Adult patients segment is expected to dominate the market with a market share of 72.15% due to the higher prevalence of cardiovascular diseases and hypercholesterolemia in the adult population. As these conditions are more common in adults, particularly those aged 40 and above, there is a significant demand for lipid-lowering therapies such as alirocumab

Report Scope and Alirocumab Market Segmentation 

Alirocumab Market Trends

“Increasing Shift Toward Personalized Cardiovascular Treatment”

• One prominent trend in the alirocumab market is the increasing shift toward personalized cardiovascular treatment, driven by the need for targeted therapies in patients with statin intolerance or high cardiovascular risk
• Alirocumab, as a PCSK9 inhibitor, offers a tailored lipid-lowering approach, particularly effective for individuals with genetic conditions such as familial hypercholesterolemia or those unresponsive to traditional statins
  • For instance, Recent clinical practices show growing physician preference for PCSK9 inhibitors in managing patients with established ASCVD and persistently elevated LDL-C levels despite maximum statin therapy, highlighting a move toward precision-based care in cardiology
• This shift toward personalized medicine is reshaping cholesterol management protocols, enhancing patient adherence and outcomes, and driving demand for therapies such as alirocumab that fit individualized treatment profiles

Alirocumab Market Dynamics

Driver

“Growing Adoption of PCSK9 Inhibitors”

• The growing adoption of PCSK9 inhibitors in treatment guidelines for cholesterol management is significantly boosting the demand for Alirocumab
• With mounting clinical evidence supporting their efficacy in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events, healthcare professionals are increasingly incorporating PCSK9 inhibitors such as alirocumab into treatment protocols for high-risk patients
• This shift is further encouraged by updated international guidelines that recommend PCSK9 inhibitors for patients who do not achieve target LDL-C levels with statins and lifestyle modifications

For instance,

• In 2022, the European Society of Cardiology (ESC) and American College of Cardiology (ACC) emphasized the role of PCSK9 inhibitors in secondary prevention for patients with established ASCVD, reinforcing their clinical relevance 
• Consequently, the integration of alirocumab into mainstream cardiovascular care is accelerating, driven by clinical endorsement and expanding physician confidence in its therapeutic benefits

Opportunity

“Rising Focus on Personalized Medicine and Genetic Profiling”

• The rising focus on personalized medicine and genetic profiling offers a significant opportunity for optimizing the use of alirocumab in managing hypercholesterolemia and cardiovascular risk
• By identifying patients with familial hypercholesterolemia (FH) or those who are genetically predisposed to elevated LDL cholesterol levels, clinicians can better target therapies such as alirocumab to those who will benefit most
• Genetic screening can also help predict patient response and tolerance to PCSK9 inhibitors, supporting precision therapy approaches that enhance treatment efficacy and reduce trial-and-error prescribing

For instance,

• In 2023, the National Human Genome Research Institute (NHGRI) highlighted ongoing research into using genomics to tailor lipid-lowering therapies, paving the way for more effective cardiovascular disease prevention in high-risk populations 
• The integration of genetic insights with alirocumab treatment protocols may lead to improved clinical outcomes, reduced adverse effects, and expanded adoption of targeted biologic therapies in lipid management

Restraint/Challenge

“Limited Awareness and Diagnosis of Familial Hypercholesterolemia”

• Limited awareness and diagnosis of familial hypercholesterolemia (FH) presents a major challenge in the alirocumab market, particularly in developing and under-resourced regions
• Despite the availability of effective therapies such as Alirocumab, many patients with genetically elevated cholesterol levels remain undiagnosed or misdiagnosed, delaying appropriate treatment
• Lack of routine lipid screening, inadequate access to genetic testing, and minimal public health initiatives targeting FH contribute to under-recognition of the condition

For instance,

• A 2022 study published in the Journal of Clinical Lipidology found that over 90% of FH cases worldwide remain undiagnosed, significantly reducing the pool of patients who could benefit from PCSK9 inhibitors such as Alirocumab 
• This diagnostic gap hampers market expansion by limiting the eligible treatment population, despite proven clinical benefits of early intervention with targeted lipid-lowering therapies

Alirocumab Market Scope

The market is segmented on the basis of indication, administration route, patient type, treatment line and distribution channel.

In 2025, the adult patients is projected to dominate the market with a largest share in patient type segment

The adult patients segment is expected to dominate the dental lasers market with the largest share of 72.15% in 2025 due to the higher prevalence of cardiovascular diseases and hypercholesterolemia in the adult population. As these conditions are more common in adults, particularly those aged 40 and above, there is a significant demand for lipid-lowering therapies such as alirocumab.

The atherosclerotic cardiovascular disease is expected to account for the largest share during the forecast period in indication segment

In 2025, the atherosclerotic cardiovascular disease segment is expected to dominate the global alirocumab market with the largest market share of 48.35% due to its high global prevalence and critical need for aggressive lipid-lowering therapies. As a leading cause of morbidity and mortality worldwide, ASCVD necessitates effective cholesterol management, and alirocumab’s proven efficacy in reducing low-density lipoprotein cholesterol (LDL-C) positions it as a key therapeutic agent

Alirocumab Market Regional Analysis

“North America Holds the Largest Share in the Alirocumab Market”

• North America is expected to dominate the global alirocumab market with a market share of approximately 64.7%, driven by the high prevalence of cardiovascular diseases, increased awareness of lipid-lowering therapies, and the strong presence of key pharmaceutical companies such as Sanofi and Regeneron
• U.S. holds a market share of 40.4%, primarily due to the widespread adoption of alirocumab for patients with atherosclerotic cardiovascular disease (ASCVD) and high cholesterol, as well as the growing prevalence of hypercholesterolemia among the adult population
• The region benefits from an advanced healthcare infrastructure, insurance coverage that supports biologic treatments, and a high rate of prescription uptake of PCSK9 inhibitors such as alirocumab
• The ongoing emphasis on improving cardiovascular health and the expanding use of Alirocumab in both preventative and therapeutic settings further strengthen its dominance in the region

“Asia-Pacific is Projected to Register the Highest CAGR in the Alirocumab Market”

• Asia-Pacific is expected to witness the highest growth rate in the global alirocumab market, with a projected market share of 24.6% in 2025, driven by the rapid expansion of healthcare infrastructure, increasing prevalence of cardiovascular diseases, and growing awareness of cholesterol-lowering therapies
• Countries such as China, India, and Japan are emerging as key markets due to rising healthcare expenditures, the growing burden of hypercholesterolemia and ASCVD, and expanding access to advanced biologics such as PCSK9 inhibitors
• Japan remains a leading market with its strong regulatory support, widespread clinical adoption of biologic lipid-lowering agents, and advanced healthcare system. The country’s focus on precision medicine and favorable reimbursement policies for high-risk cardiovascular patients further drive alirocumab uptake
• India is expected to register the highest CAGR in the alirocumab market with 2.9% market share, driven by a growing middle-class population, rising incidence of dyslipidemia and cardiovascular events, and increasing awareness of biologic treatment options. Government efforts to enhance healthcare access and affordability also support market expansion

Alirocumab Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Amgen Inc. (U.S.)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Sanofi (France)

Latest Developments in Global Alirocumab Market

• In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had expanded the approval of Praluent (alirocumab) to include pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows its use as an adjunct to diet and other LDL-C-lowering therapies in this younger population
• In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had expanded the indication for Praluent (alirocumab), approving its use as an adjunct to diet and other LDL-C-lowering therapies for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) 

SKU-73974